Recombinant EGFR (Matuzumab Biosimilar) antibody
Quick Overview for Recombinant EGFR (Matuzumab Biosimilar) antibody (ABIN7795112)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Matuzumab Biosimilar, EGFR Monoclonal Antibody
-
Characteristics
- Matuzumab Biosimilar uses the same protein sequences as the therapeutic antibody matuzumab. Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human EGFR
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- EGFR (Matuzumab Biosimilar)
-
Alternative Name
- Matuzumab Biosimilar
-
Target Type
- Biosimilar
Target
-